Trial Information

IClyCO Influence of Chemotherapy (Carboplatin and Taxol) on the ex Vivo Expansion and Functional Capacity of Gamma-delta T Cells in Patients With Epithelial Ovarian Cancer

Ovarian cancer is associated with a high mortality rate. Treatment of ovarian cancer is
currently based on surgery and chemotherapy.

The first surgery is a radical surgical procedure aiming to achieve no residual disease.
Patients who could not benefit from the first surgery may be offered neoadjuvant
chemotherapy with a new surgical procedure after 3 or 6 chemotherapy cycles. Chemotherapy is
currently based on Taxol and Carboplatin. Immunotherapy based on Vgamma9Vdelta2 T cells
could provide a promising therapeutic strategy, however, the impact of chemotherapy on the
expansion and functional abilities of Vgamma9Vdelta2 T cells has never been evaluated.

We want to study the effect of chemotherapy of ovarian cancer on Vgamma9Vdelta2 T cells
rates in the peripheral blood of patients with ovarian cancer.

Functional abilities of the Vgamma9Vdelta2 T cells will be studied: expansion after
chemotherapy and their cytotoxic abilities in an autologous context before or after
chemotherapy.

The long term goal is to give a rational to combine conventional treatment of ovarian cancer
with non-conventional treatment such as immunotherapy based on Vgamma9Vdelta2 T cells.